CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that it has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI’s annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market® that meet NBI’s eligibility criteria. NantKwest will be added to the NBI effective prior to market open on December 18, 2015.
